Cargando…
The current management and biomarkers of immunotherapy in advanced gastric cancer
BACKGROUND: Gastric carcinoma (GC) is the fourth most common cause of cancer-related death worldwide. Most patients are diagnosed at later stage, because of few treatment options, the prognosis is poor. In recent years, however, Immune checkpoint inhibitors(ICIs), such as anti- programmed death-1 (P...
Autores principales: | Chang, Xiaojing, Ge, Xiaohui, Zhang, Yufeng, Xue, Xiaoying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276259/ https://www.ncbi.nlm.nih.gov/pubmed/35623069 http://dx.doi.org/10.1097/MD.0000000000029304 |
Ejemplares similares
-
Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis
por: Yuan, Xin, et al.
Publicado: (2021) -
Do patients receive any benefit from the addition of perioperative immunotherapy-chemotherapy for solid tumors?
por: Quan, Rencui, et al.
Publicado: (2023) -
Sublingual Immunotherapy for Asthmatic Children Sensitized to House Dust Mite: A Meta-Analysis
por: Liao, Wei, et al.
Publicado: (2015) -
Mapping current status and emerging trends in NETosis: A bibliometric study
por: Wang, Hongqin, et al.
Publicado: (2023) -
The serum interleukin-26 level is a potential biomarker for chronical hepatitis B
por: Luo, Liwen, et al.
Publicado: (2020)